Form 4: CRISPR CEO Kulkarni's RSU Vesting & Tax-Related Share Sale

CRISPR Therapeutics CEO Samarth Kulkarni acquired 25,000 shares through RSU vesting and subsequently sold 13,081 shares to cover tax obligations.

Summary

• Samarth Kulkarni, CEO and Director of CRISPR Therapeutics AG, acquired 25,000 Common Shares on August 16, 2025, through the vesting of Restricted Stock Units (RSUs).
• These RSUs were granted on August 16, 2022, and vested 100% on August 16, 2025.
• On August 18, 2025, Kulkarni sold 13,081 Common Shares at a price of $58.15 per share.
• This sale was not a discretionary trade but was mandated by the company's RSU Settlement Policy to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Kulkarni directly owns 207,004 Common Shares and indirectly owns 85,622 Common Shares through The Kulkarni 2023 GRAT.

Sentiment

Score: 7

Explanation: The filing indicates a routine, non-discretionary transaction related to executive compensation. The RSU vesting is a positive for the executive, and the associated sale for tax purposes is a neutral event, not signaling a lack of confidence.

Positives

• Vesting of 25,000 Restricted Stock Units for CEO Samarth Kulkarni, indicating a planned compensation event.
• The sale of 13,081 shares was non-discretionary and solely for tax withholding, not a signal of lack of confidence.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units.
• This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Industry Context

This filing is a routine insider transaction related to executive compensation and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes is a routine event and does not indicate a change in management's confidence or strategy. The CEO's overall beneficial ownership remains substantial.
• Employees: The RSU vesting demonstrates the company's compensation structure for executives.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary insider transaction related to executive compensation. The CEO's acquisition of shares through RSU vesting and subsequent sale to cover tax obligations is a standard event and does not provide new information that would warrant a change in investment recommendation. It does not signal a lack of confidence from the CEO, nor does it present new positive or negative operational or financial data. Therefore, a "hold" recommendation is appropriate as this filing does not alter the fundamental investment thesis for CRSP.

Keywords

CRISPR Therapeutics, CRSP, Samarth Kulkarni, CEO, Director, SEC Form 4, Insider Transaction, RSU Vesting, Share Sale, Tax Withholding, Beneficial Ownership